skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update

Review

(4147) Views  (1164) Full article downloads

Authors: Maurizio Destro, Francesca Cagnoni, Antonio D’Ospina, et al

Published Date April 2010 Volume 2010:6 Pages 253 - 260
DOI: http://dx.doi.org/10.2147/VHRM.S6805

Maurizio Destro1, Francesca Cagnoni1, Antonio D’Ospina1, Alessandra Rossi Ricci1, Elena Demichele1, Emmanouil Peros1, Augusto Zaninelli2, Paola Preti3

1Internal Medicine, Ospedale Unificato Broni-Stradella, Stradella (PV), Italy; 2General Medicine, School of Medicine, University of Florence, Florence, Italy; 3Internal Medicine, University of Pavia, Pavia, Italy

Abstract: The treatment of moderate or severe hypertension in most cases requires the contemporaneous use of multiple antihypertensive agents. The most available two-drug combinations have an agent that addresses renin secretion and another one that is statistically more effective in renin-independent hypertension. The practice of combining agents that counteract different mechanisms is the most likely explanation for the fact that most available two-drug combinations have an agent that addresses renin secretion (beta-blocker, angiotensin converting enzyme inhibitor, angiotensin II receptor blocker or direct renin inhibitor) and another one that is more effective in renin-independent hypertension (diuretic, dihydropyridine or non-dihydropyridine calcium channel blocker). Based on these considerations, addition of hydrochlorothiazide to the combination of an antagonist of the renin-angiotensin system with a calcium channel blocker would constitute a logical approach. Inclusion of a diuretic in the triple combination is based on the evidence that these agents are effective and cheap, enhance the effect of other antihypertensive agents, and add a specific effect to individuals with salt-sensitivity of blood pressure. The benefit of triple combination therapy with amlodipine, valsartan and hydrochlorothiazide over its dual component therapies has been demonstrated, and the use of a single pill will simplify therapy resulting in better blood pressure control.

Keywords: valsartan, amlodipine, hydrochlorothiazide, HCTZ, blood pressure, hypertension






 

Other articles by Dr Maurizio Destro



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine
Optimizing blood pressure control through the use of fixed combinations
Aliskiren and valsartan combination therapy for the management of hypertension
Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice
Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients
A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University